GlassScriptPhysician profile
Henry J Chen
NPI 1750351169
$7,860.25
in general payments reported to CMS, 2019-2025
29 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,110 · 2020: $762 · 2021: $659 · 2022: $1,074 · 2023: $775 · 2024: $1,352 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,254.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,899.48 | 2019-2025 | |
| Boston Scientific Corporation | $946.25 | 2019-2025 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon, Rotapro |
| Janssen Pharmaceuticals, INC | $789.93 | 2019-2024 | Xarelto |
| Amgen INC. | $583.90 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $549.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.36 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $284.78 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $230.38 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $209.94 | 2019-2025 | Wainua, Farxiga |
| Gilead Sciences, INC. | $206.78 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $197.66 | 2019-2025 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $184.63 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $183.47 | 2024-2025 | Lifevest |
| Cardiovascular Systems INC. | $168.93 | 2020-2022 | |
| Medtronic, INC. | $162.60 | 2021-2025 | Onyx Frontier |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $158.72 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $135.66 | 2019 | |
| Abbott Laboratories | $119.20 | 2020-2025 | Gallant, Optis, Mitraclip |
| Esperion Therapeutics, INC. | $112.07 | 2020-2023 | Nexletol |
| Abiomed | $52.26 | 2025 | |
| Chiesi USA, INC. | $51.79 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $43.86 | 2023 | Uptravi |
| Lundbeck LLC | $34.46 | 2019 | |
| United Therapeutics Corporation | $31.56 | 2025 | Remodulin, Orenitram |
| Lexicon Pharmaceuticals, INC. | $22.40 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $17.93 | 2024 | |
| Merck Sharp & Dohme LLC | $17.83 | 2023 | Verquvo |
| Shockwave Medical, INC | $17.82 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Siemens Medical Solutions USA, INC. | $17.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.